Geoffrey R. Oxnard, M.D., Assistant Professor, Dana-Farber Cancer Institute, Harvard Medical School, discusses his research into resistance development of non-small cell lung cancers to Osimertinib. Hear how the detection of key mutations in cell-free DNA from liquid biopsies helps improve understanding of resistance development, as well as inform treatment decisions. In the future Oxnard hopes his research will help to provide personalized treatment strategies for cancer patients.